Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Con...
Upstream Bio, Inc. (UPB)
Company Research
Source: Yahoo! Finance
– Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes – – Data support the potential of verekitug's unique mechanism of action to achieve a differentiated therapeutic effect across a broad range of TSLP-driven severe respiratory diseases – WALTHAM, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing verekitug's potent pharmacodynamic activity through its unique approach of targeting the thymic stromal lymphopoietin (TSLP) receptor. Data were presented at the European Respiratory Society (ERS) Congress being held September 27 – October 1, 2025, in Amsterdam, Netherlands. “We continue to deepen our understanding of verekitug's unique TSLP receptor-targeting mechanism and its role in driving the rapid and d
Show less
Read more
Impact Snapshot
Event Time:
UPB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UPB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UPB alerts
High impacting Upstream Bio, Inc. news events
Weekly update
A roundup of the hottest topics
UPB
News
- Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.MarketBeat
- Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Participate in Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Participate in Upcoming December Investor ConferencesGlobeNewswire
- Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued ProgressGlobeNewswire
UPB
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form S-3ASR
- UPB's page on the SEC website